BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 10871894)

  • 1. Potential new treatments for type 2 diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2000 Jul; 21(7):259-65. PubMed ID: 10871894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
    Hofmann CA; Colca JR
    Diabetes Care; 1992 Aug; 15(8):1075-8. PubMed ID: 1505314
    [No Abstract]   [Full Text] [Related]  

  • 3. Current views on the mechanism of action of thiazolidinedione insulin sensitizers.
    Goldstein BJ
    Diabetes Technol Ther; 1999; 1(3):267-75. PubMed ID: 11475273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating hyperglycemia in type 2 diabetes: new goals and strategies.
    Lebovitz HE
    Cleve Clin J Med; 2002 Oct; 69(10):809-20. PubMed ID: 12371804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone.
    Balfour JA; Plosker GL
    Drugs; 1999 Jun; 57(6):921-30; discussion 931-2. PubMed ID: 10400405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
    Rosak C
    J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of glycemic control: a feature of the thiazolidinediones.
    Serdy S; Abrahamson MJ
    Diabetes Technol Ther; 2004 Apr; 6(2):179-89. PubMed ID: 15117584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
    Vasudevan AR; Balasubramanyam A
    Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
    Phillips JW; Barringhaus KG; Sanders JM; Yang Z; Chen M; Hesselbacher S; Czarnik AC; Ley K; Nadler J; Sarembock IJ
    Circulation; 2003 Oct; 108(16):1994-9. PubMed ID: 14517165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications.
    Porte D
    Diabetes Metab Res Rev; 2001; 17(3):181-8. PubMed ID: 11424231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance, diabetes, and the adipocyte.
    Stolar MW
    Am J Health Syst Pharm; 2002 Dec; 59 Suppl 9():S3-8. PubMed ID: 12489380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes mellitus.
    DeFronzo RA; Ferrannini E; Groop L; Henry RR; Herman WH; Holst JJ; Hu FB; Kahn CR; Raz I; Shulman GI; Simonson DC; Testa MA; Weiss R
    Nat Rev Dis Primers; 2015 Jul; 1():15019. PubMed ID: 27189025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
    Pathak R; Afaq A; Blonde L
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S483-94. PubMed ID: 12408411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.